The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 14, 2007

Filed:

Jan. 20, 2004
Applicants:

Tohru Kambe, Mishima-gun, JP;

Toru Maruyama, Mishima-gun, JP;

Kaoru Kobayashi, Mishima-gun, JP;

Kousuke Tani, Mishima-gun, JP;

Yoshihiko Nakai, Mishima-gun, JP;

Toshihiko Nagase, Mishima-gun, JP;

Takayuki Maruyama, Mishima-gun, JP;

Kiyoto Sakata, Mishima-gun, JP;

Hideyuki Yoshida, Mishima-gun, JP;

Shinsei Fujimura, Mishima-gun, JP;

Akio Nishiura, Mishima-gun, JP;

Nobutaka Abe, Mishima-gun, JP;

Inventors:

Tohru Kambe, Mishima-gun, JP;

Toru Maruyama, Mishima-gun, JP;

Kaoru Kobayashi, Mishima-gun, JP;

Kousuke Tani, Mishima-gun, JP;

Yoshihiko Nakai, Mishima-gun, JP;

Toshihiko Nagase, Mishima-gun, JP;

Takayuki Maruyama, Mishima-gun, JP;

Kiyoto Sakata, Mishima-gun, JP;

Hideyuki Yoshida, Mishima-gun, JP;

Shinsei Fujimura, Mishima-gun, JP;

Akio Nishiura, Mishima-gun, JP;

Nobutaka Abe, Mishima-gun, JP;

Assignee:
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 31/40 (2006.01); A61K 31/426 (2006.01); C07D 207/12 (2006.01); C07D 207/36 (2006.01);
U.S. Cl.
CPC ...
Abstract

The pharmaceutical composition comprising the compound of the invention having 8-azaprostaglandin skeleton represented by formula (I) (wherein, all the symbols have the same meanings as that of the specification) a salt thereof, a solvate thereof or a cyclodextrin clathrate thereof, or a prodrug thereof and them as active ingredient have EPagonistic action and thus are considered useful for the prevention and/or treatment of immunological diseases, asthma, neuronal cell death, arthritis, lung failure, pulmonary fibrosis, pulmonary emphysema, bronchitis, chronic obstructive pulmonary disease, liver damage, acute hepatitis, nephritis, renal insufficiency, hypertension, myocardial ischemia, systemic inflammatory response syndrome, sepsis, hemophagous syndrome, macrophage activation syndrome, Still's disease, Kawasaki disease, burn, systemic granulomatosis, ulcerative colitis, Crohn's disease, hypercytokinemia at dialysis, multiple organ failure, shock and glaucoma, etc. Furthermore, the compounds also have an action of accelerating bone formation, so it is expected to be useful for the prevention and/or treatment of diseases associated with loss in bone mass, for example, primary osteoporosis, secondary osteoporosis, bone metastasis of cancer, hypercalcemia, Paget's disease, bone loss, osteonecrosis, bone formation after bone operation, alternative treatment for bone grafting.


Find Patent Forward Citations

Loading…